Teva has appointed Timothy Wright as its new head of business development, strategy and innovation.
He joins the Israeli pharma company from The Ohio State University Comprehensive Cancer Center, where he served as director of its Drug Discovery and Development Institute.
Prior to that Wright spent more than 25 years in pharma and biotech, most recently as president of Covidien Pharma from 2007-10.
Before that he was CEO (Interim) and Presidentat AAI Pharmaceuticals/Xanodyne and held various roles at Elan Pharmaceuticals and DuPont Merck Pharmaceutical Company.
In his new, newly-created role Wright, whose appointment will be effective from April 13, will be responsible for identifying new sources of innovation and growth that are extensions of Teva’s current business model.
Erez Vigodman, Teva’s president and CEO, said: “The addition of Tim to our leadership team complements the strong management capabilities we have in Teva. He has a wealth of global experience which will serve us well as we look to create a new and exciting future for Teva.
“Tim is known for leading the transformation of large companies. His significant experience across various aspects of healthcare and unique perspective will enable us to realise our full potential at this critical time of change in the pharmaceutical industry.”